Full Press Release Details
| Dr. Reddy's Laboratories Ltd. | |
| 8-2-337, Road No. 3, Banjara Hills, | |
| Hyderabad - 500 034, Telangana, | |
| India. | |
| CIN: L85195TG1984PLC004507 | |
| Tel :+91 40 4900 2900 | |
| Fax :+91 40 4900 2999 | |
| Email :mail@drreddys.com | |
| www.drreddys.com |
| Corporate Relationship Department | National Stock Exchange of India Ltd. | |||
| BSE Limited | "Exchange Plaza" | |||
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), | |||
| Mumbai - 400 001 | Mumbai - 400 051 | |||
| Fax Nos.: | 022-22723121 / 22723719 / | Fax Nos.: | 022-26598120/ 26598237/ | |
| 22722037 / 22722039 | 26598238 | |||
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Please find enclosed a Press Release on
"Dr. Reddy's Laboratories announces filing of Annual Report on Form 20-F"
This is for your information.
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |
CC:- New York Stock Exchange Inc.(Stock Code :RDY)
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
| 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. | AMIT AGARWAL amita@drreddys.com (Ph: +91-40-49002135) | MITALI SARKAR mitali.sarkar@drreddys.com (Ph: +91-40- 49002121) |
Laboratories Limited announces filing of
India, June 3, 2019: Dr. Reddy's Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced that its Annual
Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended March 31, 2019 was filed
with the United States Securities and Exchange Commission on June 3, 2019.
on Form 20-F is also available on Dr. Reddy's website, www.drreddys.com and can be accessed by selecting SEC filings'
under Reports and Filings' section under Investors'. ADS holders may also obtain a hard copy of the
Annual Report on Form 20-F at no cost, by sending a written request to the Company's registered office or by sending an
e-mail to shares@drreddys.com.
About Dr. Reddy's: Dr. Reddy's
Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable
and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients,
Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs,
custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are
gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets
across the globe. Our major markets include - USA, India, Russia & CIS countries, and Europe. For more information,
log on to: www.drreddys.com
Disclaimer: This press release may include
statements of future expectations and other forward-looking statements that are based on the management's current views
and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to
differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason
of context, the words "may", "will", "should", "expects", "plans", "intends",
"anticipates", "believes", "estimates", "predicts", "potential", or "continue"
and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from
those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets,
credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events
(ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes
in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization
, including related integration issues.
The company assumes no obligation to update
any information contained herein.